Table 1.
Patients’ baseline characteristics
| All patients (n = 37) | DMARD cohort (n = 24) | Biologics cohort (n = 13) | |
|---|---|---|---|
| Male/female | 7/30 | 5/19 | 2/11 |
| Age (years) | 13.9 (2.2) | 14.3 (2.1) | 13.5 (2.4) |
| Disease duration (years) | 3.6 (3.2) | 3.2 (4.1) | 4.1 (3.7) |
| CHAQ-DI | 0.61 (0.7) | 0.54 (0.58) | 0.66 (0.84) |
| JADAS 10 | 16.9 (5.7) | 15.5 (5.6) | 19.0 (5.0) |
| ESR (mm/h) | 17.6 (20.1) | 18.9 (21.8) | 14.4 (15) |
| CRP(mg/l) | 5.0 (12.2) | 2.7 (4.5) | 8.7 (18.3) |
| Physician Global Assessment VAS (cm) | 4.8 (2.1) | 4.4 (1.8) | 5.5 (2.3) |
| Parents Global Assessment VAS (cm) | 4.5 (2.5) | 4.5 (2.1) | 4.5 (3.2) |
| Number of active joints | 7.1 (5.2) | 6.7 (5.2) | 8.3 (5.0) |
| Number of tender joints | 9.6 (8.9) | 9.6 (8.0) | 10.0 (11.4) |
| Number of swollen joints | 7.2 (5.7) | 6.8 (5.7) | 8.1 (5.5) |
| Number of joints with LOM | 6.5 (6.7) | 5.4 (5.3) | 8.4 (8.4) |
Data presented as number or mean (standard deviation)
DMARD disease-modifying antirheumatic drug, CHAQ Childhood Health Assessment Questionnaire, CRP C-reactive protein, ESR erythrocyte sedimentation rate, JADAS Juvenile Diseases Activity Score, LOM limitation of motion, VAS visual analog scale